X0306 4 2014-09-30 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001242825 LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2014-09-30 4 M 0 200000 29.98 A 344992 D Common Stock 2014-09-30 4 S 0 24729 111.31 D 320263 D Common Stock 2014-09-30 4 S 0 79817 112.21 D 240446 D Common Stock 2014-09-30 4 S 0 53750 113.10 D 186696 D Common Stock 2014-09-30 4 S 0 41704 113.90 D 144992 D Common Stock 440 I 401(k) Stock Option (right to buy) 29.98 2014-09-30 4 M 0 200000 0.00 D 2021-12-13 Common Stock 200000 213108 D Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $111.31 (range $110.61 to $111.60). Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $112.21 (range $111.61 to $112.60). Open market sales reported on this line occurred at a weighted average price of $113.10 (range $112.61 to $113.60). Open market sales reported on this line occurred at a weighted average price of $113.90 (range $113.61 to $114.41). The option vests in 16 quarterly installments from 12/14/2011. Kenneth L. Horton, Attorney-In-Fact 2014-10-01